Since activation of AKT by EGFR suppresses GSK3β activity through Ser9 phosphorylation35, inhibition of EGF signalling in BLBC cells creates a therapeutic benefit by reducing cancer cell immune escape via PD-L1 destabilization. The gene discussed is GSK3B; the disease is cancer.